Saundra Pelletier
About Saundra Pelletier
Saundra Pelletier is a seasoned biopharma executive and board member focused on women’s health. She was appointed to the IMAC Holdings (ticker: BACK) Board of Directors on June 2, 2025 . She is CEO of Evofem Biosciences and holds a BS in Business Administration and an honorary Doctor of Business Administration from Husson University; she also has a BS in Communications from the New England School of Communications . At Windtree Therapeutics in 2024 she was disclosed at age 55, which provides an approximate current age reference .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Evofem Biosciences (EVFM) | CEO, President, Executive Director | ~2013–present | Led public market transition; product approvals and acquisitions; consecutive net sales growth |
| WomanCare Global | Founding CEO | 2009–2016 | Built sustainable supply chains delivering reproductive health products globally |
| G.D. Searle | Corporate VP & Global Franchise Leader (Women’s Health) | ~8 years (early career) | Managed global franchise in women’s healthcare |
External Roles
| Company | Role | Appointment/Status | Committees |
|---|---|---|---|
| Windtree Therapeutics (WINT) | Independent Director | Appointed Aug 13, 2024 | Chair, Compensation; Member, Audit; Member, Nominating & Corporate Governance |
| TRACON Pharmaceuticals (TCON) | Director (Class I) | Appointed Mar 14, 2020; re‑election 2022 | Audit Member; Chair, Nominating & Corporate Governance (as of 2021) |
| Aditxt (ADTX) | Director | Appointed June 5, 2025 | Committees not disclosed; board appointment confirmed |
| Evofem Biosciences (EVFM) | CEO; Director (Class III nominated 2023) | Ongoing | Board nomination disclosed; committee status not specified |
Board Governance
- Appointment and independence: IMAC (BACK) appointed Pelletier on June 2, 2025; the filing states no family relationships and no transactions requiring disclosure under Item 404(a), which reduces related‑party conflict risk, though the filing does not explicitly state an “independent” determination for BACK .
- Committee assignments at BACK: Not disclosed in the June 2025 8‑K or the February 2025 proxy materials retrieved; most recent disclosed committee composition prior to her appointment (FY2023) was Audit: Michael D. Pruitt (Chair), Maurice E. Evans, Cary W. Sucoff; Compensation: Evans (Chair), Pruitt, Sucoff; Nominating & Governance: Sucoff (Chair), Evans, Pruitt .
- Board leadership and attendance context: Sucoff was disclosed as Interim Chairman in 2024 . Committee meeting frequency in 2023: Audit met 4 times; Compensation met 1 time; Nominating & Governance met 1 time .
- Executive sessions, board meeting attendance, and lead independent director status: Not disclosed in the documents retrieved.
Fixed Compensation
Context from BACK’s most recent available director compensation (pre‑Pelletier appointment):
| Metric | FY 2021 | FY 2023 |
|---|---|---|
| Annual cash fees per director ($) | $38,833 | $45,000 |
| RSUs per director (units) | 100,000 (awarded to each director; narrative disclosure) | 3,333 (immediate vesting) |
| Stock awards fair value per director ($) | — (table shows “$ -”) | $14,300 (RSU grant-date fair value) |
Notes: BACK disclosed in 2023 that non‑employee directors received $11,250 per quarter and 3,333 RSUs vesting immediately . Earlier narrative indicates 100,000 RSUs granted in 2021 and again in 2022 with immediate vesting, while the 2021 compensation table shows no stock award amounts; this inconsistency likely reflects timing/measurement differences or classification across filings .
Performance Compensation
| Performance Metric | FY 2021 | FY 2023 |
|---|---|---|
| Performance‑based equity (PSUs) | Not disclosed for non‑employee directors | Not disclosed for non‑employee directors; RSUs vests immediately (time‑based) |
| Cash bonus tied to KPIs | Not disclosed | Not disclosed |
No performance metrics (TSR, revenue growth, EBITDA, ESG) are disclosed as determinants of director pay at BACK in the periods reviewed; director equity appears to be time‑based RSUs, which reduces explicit pay‑for‑performance linkage .
Other Directorships & Interlocks
| Company | Sector | Role & Committees | Potential Interlock/Conflict Considerations |
|---|---|---|---|
| Windtree Therapeutics (WINT) | Biotech | Comp Chair; Audit; Nominating & Governance | Governance leadership experience; increases time commitments |
| TRACON Pharmaceuticals (TCON) | Biotech/Oncology | Audit; Chair Nominating & Governance | Strong governance exposure; time commitment |
| Aditxt (ADTX) | Health innovation | Director (committees not disclosed) | New 2025 appointment adds another board seat |
| Evofem Biosciences (EVFM) | Women’s health | CEO; Director nominee (Class III, 2023) | Executive role plus directorship can strain bandwidth |
Expertise & Qualifications
- Deep women’s health commercialization expertise; led Evofem through public transition, FDA approval of PHEXXI and acquisition of SOLOSEC, with four consecutive years of net sales growth .
- Early career global franchise leadership at G.D. Searle in women’s healthcare .
- Governance credentials: Committee leadership at WINT (Compensation Chair) and TCON (Nominating & Governance Chair), plus Audit committee service at both organizations .
- Education: BS Business Administration and honorary DBA (Husson University); BS Communications (New England School of Communications) .
Equity Ownership
- BACK beneficial ownership: Pelletier’s specific equity ownership at BACK was not disclosed in the 2025 proxy materials reviewed; the 2025 DEF 14A security ownership table did not list Pelletier, likely due to record date timing prior to her June 2025 appointment .
- Form 4/insider transactions: No Form 4 transactions retrieved for BACK during June–Nov 2025 in our attempt; Item 404(a) disclosures in the June 2025 8‑K note no related party transactions for Pelletier .
Governance Assessment
- Positive signals
- No family relationships and no Item 404(a) related‑party transactions at appointment, reducing conflict risk at BACK .
- Strong governance experience across other public boards, including service on Audit and chairing Compensation and Nominating/Governance, indicating familiarity with key oversight functions .
- Watch items / potential red flags
- Overboarding risk: Concurrent roles at multiple public companies (WINT, TCON, ADTX) while serving as CEO of EVFM may strain capacity for committee work and meeting attendance at BACK; current BACK attendance/committee assignments are not yet disclosed to evaluate engagement .
- Pay‑for‑performance alignment for directors: BACK’s non‑employee director equity is time‑based RSUs with immediate vesting and no disclosed performance metrics, which weakens incentive alignment vs. performance‑linked awards .
- Committee coverage at BACK
- As of the latest pre‑appointment proxy (FY2023), committees were led by Pruitt/Evans/Sucoff; Pelletier’s committee assignments have not yet been disclosed, limiting visibility into her direct governance impact at BACK .
Overall: Pelletier brings relevant commercialization and governance expertise that should strengthen board effectiveness, but investors should monitor overboarding and seek disclosure of BACK committee assignments, attendance, and director equity ownership to gauge alignment and engagement going forward .